CN Patent

CN104363899A — [(1s)-1-{[(2s,4r)-4-(7-氯-4-甲氧基异喹啉-1-基氧基)-2-({(1r,2s)-1-[(环丙基磺酰基)氨甲酰基]-2-乙烯基环丙基}氨甲酰基)吡咯烷-1-基]羰基}-2,2-二甲基丙基]氨基甲酸1,1-二甲基乙基酯的增溶的胶囊制剂

Assigned to Bristol Myers Squibb Holdings Ireland ULC · Expires 2015-02-18 · 11y expired

What this patent protects

本发明包括多个实施方案，其涉及阿舒瑞韦[(1S)-1-{[(2S,4R)-4-(7-氯-4-甲氧基异喹啉-1-基氧基)-2-({(1R,2S)-1-[(环丙基磺酰基)氨甲酰基]-2-乙烯基环丙基}氨甲酰基)吡咯烷-1-基]羰基}-2,2-二甲基丙基]氨基甲酸1,1-二甲基乙基酯的增溶的胶囊制剂，并涉及包括阿舒瑞韦的方法。

USPTO Abstract

本发明包括多个实施方案，其涉及阿舒瑞韦[(1S)-1-{[(2S,4R)-4-(7-氯-4-甲氧基异喹啉-1-基氧基)-2-({(1R,2S)-1-[(环丙基磺酰基)氨甲酰基]-2-乙烯基环丙基}氨甲酰基)吡咯烷-1-基]羰基}-2,2-二甲基丙基]氨基甲酸1,1-二甲基乙基酯的增溶的胶囊制剂，并涉及包括阿舒瑞韦的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN104363899A
Jurisdiction
CN
Classification
—
Expires
2015-02-18
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Holdings Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.